Pharming Group (PHAR)
(Delayed Data from NSDQ)
$8.00 USD
+0.58 (7.82%)
Updated Aug 14, 2024 02:22 PM ET
4-Sell of 5 4
C Value F Growth A Momentum D VGM
Income Statements
Fiscal Year end for Pharming Group NV Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 245 | 206 | 199 | 212 | 189 |
Cost Of Goods | 25 | 18 | 21 | 24 | 24 |
Gross Profit | 220 | 188 | 178 | 189 | 165 |
Selling & Adminstrative & Depr. & Amort Expenses | 225 | 170 | 164 | 112 | 97 |
Income After Depreciation & Amortization | -5 | 18 | 14 | 76 | 68 |
Non-Operating Income | -7 | -3 | 10 | -32 | -16 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -12 | 15 | 23 | 44 | 52 |
Income Taxes | -1 | 1 | 7 | 6 | 12 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -11 | 14 | 16 | 38 | 41 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -11 | 14 | 16 | 38 | 41 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 11 | 31 | 33 | 85 | 74 |
Depreciation & Amortization (Cash Flow) | 16 | 13 | 20 | 8 | 6 |
Income After Depreciation & Amortization | -5 | 18 | 14 | 76 | 68 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 67.46 | 71.97 | 64.23 | 64.03 | NA |
Diluted EPS Before Non-Recurring Items | -0.14 | 0.03 | 0.19 | 0.58 | NA |
Diluted Net EPS (GAAP) | -0.16 | 0.19 | 0.23 | 0.55 | 0.60 |
Fiscal Year end for Pharming Group NV Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 74.10 | 55.59 | 81.20 | 66.70 | 54.90 |
Cost Of Goods | 8.00 | 8.39 | 7.14 | 8.30 | 5.70 |
Gross Profit | 66.10 | 47.20 | 74.04 | 58.40 | 49.20 |
SG&A, R&D, and Dept/Amort Expenses | 69.20 | 63.51 | 72.96 | 56.50 | 43.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.10 | -16.31 | 1.08 | 1.90 | 5.30 |
Non-Operating Income | 3.00 | -0.31 | -3.11 | 1.40 | -1.90 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -0.10 | -16.62 | -2.04 | 3.30 | 3.40 |
Income Taxes | 1.10 | -4.18 | 1.10 | -0.20 | 2.10 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.20 | -12.45 | -2.70 | 3.50 | 1.32 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.20 | -12.45 | -2.70 | 3.50 | 1.32 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 91.29 | 65.52 | 67.50 | 69.28 | 65.95 |
Diluted EPS Before Non-Recurring Items | -0.01 | -0.19 | -0.03 | 0.05 | 0.02 |
Diluted Net EPS (GAAP) | -0.02 | -0.19 | -0.04 | 0.05 | 0.02 |